Looks like there`s been an error while trying to load this page.
Our team has been notified but please contact us using the email support widget if the problem persists.
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM P/E Multiple | 40.2x - 44.4x | 42.3x |
| Selected Fwd P/E Multiple | 35.5x - 39.2x | 37.3x |
| Fair Value | ₹25,564 - ₹28,255 | ₹26,909 |
| Upside | -13.9% - -4.9% | -9.4% |
| Benchmarks | - | Full Ticker |
| Lupin Limited | 50,025,700.0% | BSE:500257 |
| Mankind Pharma Limited | 54,390,400.0% | BSE:543904 |
| Alembic Pharmaceuticals Limited | 53,357,300.0% | BSE:533573 |
| Novartis India Limited | 50,067,200.0% | BSE:500672 |
| Medico Remedies Limited | 54,093,700.0% | BSE:540937 |
| Abbott India Limited | - | NSEI:ABBOTINDIA |
| - | - | - |
| Select Price / LTM EPS Ratio | ||||||||
| Benchmark Companies | ||||||||
| 500257 | 543904 | 533573 | 500672 | 540937 | ABBOTINDIA | |||
| BSE:500257 | BSE:543904 | BSE:533573 | BSE:500672 | BSE:540937 | NSEI:ABBOTINDIA | |||
| Historical Net Income Growth | ||||||||
| 5Y CAGR | 30.2% | 27.0% | 1.1% | 10.5% | 39.5% | 21.7% | ||
| 3Y CAGR | 16.3% | 14.8% | -18.7% | 59.7% | 47.4% | 20.3% | ||
| Latest Twelve Months | 60.2% | 18.2% | 2.5% | -9.7% | 27.2% | 16.5% | ||
| Historical Net Income Profit Margin | ||||||||
| 5 Year Average Margin | 3.0% | 17.7% | 12.3% | 14.0% | 4.0% | 17.6% | ||
| Prior Fiscal Year | 2.6% | 14.7% | 6.1% | 27.3% | 5.2% | 17.8% | ||
| Latest Fiscal Year | 9.6% | 18.5% | 9.9% | 25.4% | 5.7% | 20.5% | ||
| Latest Twelve Months | 13.0% | 17.5% | 9.4% | 24.4% | 5.9% | 21.4% | ||
| Current Trading Multiples | ||||||||
| EV / LTM EBITDA | 18.2x | 35.1x | 18.8x | 17.5x | 37.9x | 40.1x | ||
| Price / LTM Sales | 4.2x | 9.1x | 2.7x | 5.7x | 3.1x | 10.1x | ||
| LTM P/E Ratio | 32.1x | 51.7x | 28.5x | 23.4x | 52.7x | 47.4x | ||
| Low | Mid | High | ||||||
| Benchmark LTM P/E Ratio | 23.4x | 32.1x | 52.7x | |||||
| Historical LTM P/E Ratio | 49.1x | 50.5x | 55.2x | |||||
| Selected P/E Multiple | 40.2x | 42.3x | 44.4x | |||||
| (x) LTM Net Income | 13,345 | 13,345 | 13,345 | |||||
| (=) Equity Value | 536,238 | 564,461 | 592,684 | |||||
| (/) Shares Outstanding | 21.2 | 21.2 | 21.2 | |||||
| Implied Value Range | 25,235.55 | 26,563.74 | 27,891.93 | |||||
| FX Rate: INR/INR | 1.0 | 1.0 | 1.0 | Market Price | ||||
| Implied Value Range (Trading Cur) | 25,235.55 | 26,563.74 | 27,891.93 | 29,705.00 | ||||
| Upside / (Downside) | -15.0% | -10.6% | -6.1% | |||||
| Equity Value | |||||||
| Benchmark Companies | |||||||
| (in millions) | 500257 | 543904 | 533573 | 500672 | 540937 | ABBOTINDIA | |
| Value of Common Equity | 921,508 | 1,052,756 | 172,081 | 20,206 | 4,662 | 631,211 | |
| (/) Shares Outstanding | 456.6 | 412.6 | 196.6 | 24.7 | 83.0 | 21.2 | |
| Implied Stock Price | 2,018.35 | 2,551.65 | 875.45 | 818.35 | 56.18 | 29,705.00 | |
| FX Conversion Rate to Trading Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |
| Implied Stock Price (Trading Cur) | 2,018.35 | 2,551.65 | 875.45 | 818.35 | 56.18 | 29,705.00 | |
| Trading Currency | INR | INR | INR | INR | INR | INR | |
| FX Rate to Reporting Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |